Controversial disease dropped from Prozac product information

Ray Moynihan*

*Corresponding author for this work

Research output: Contribution to journalArticleProfessional

11 Citations (Scopus)


The drug manufacturer Lilly has been forced to drop one of the disorders it had previously listed for its antidepressant drug fluoxetine (Prozac), following a finding by the European drug regulator that the condition was not a well-established disease entity.

Some health researchers welcomed the regulator's decision, saying premenstrual dysphoric disorder (PMDD), which was only recently described, was an invented illness and a strong example of the medicalisation of ordinary life.
Original languageEnglish
Pages (from-to)365-365
Number of pages1
JournalBMJ (Clinical research ed.)
Issue number7436
Publication statusPublished - 14 Feb 2004


Dive into the research topics of 'Controversial disease dropped from Prozac product information'. Together they form a unique fingerprint.

Cite this